{"id":55642,"date":"2023-04-10T15:05:29","date_gmt":"2023-04-10T13:05:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/"},"modified":"2023-04-10T15:05:29","modified_gmt":"2023-04-10T13:05:29","slug":"tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/","title":{"rendered":"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>The genetic tuning innovator adds pioneering genetic medicine expert and an accomplished <\/i><i>biotechnology lawyer to its management team.<\/i><\/p>\n<p>DURHAM, N.C. &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Today, leading epigenomic editing company <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftunetx.com%2F&amp;esheet=53377145&amp;newsitemid=20230410005075&amp;lan=en-US&amp;anchor=Tune+Therapeutics&amp;index=1&amp;md5=27e43e2187ef7d813ecf78749eabdb08\" rel=\"nofollow noopener\" shape=\"rect\">Tune Therapeutics<\/a> introduced two members to its leadership team: Chief Scientific Officer, Derek Jantz, Ph.D., and General Counsel, Zachary Hale, J.D.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758977\/5\/derek.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758977\/21\/derek.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758976\/5\/tune_logo-FULL.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758976\/21\/tune_logo-FULL.jpg\"><\/a><\/p>\n<p>\nDr. Jantz comes to Tune with deep expertise in developing cell and gene therapeutic candidates through the use of innovative genomic technologies. Hale joins the company after over a decade of specialized legal work with biotechnology startups.<\/p>\n<p>\nTune\u2019s genetic tuning platform, TEMPO, enables precise and durable changes to gene expression without risking permanent, off-target mutations across the genome. Dr. Jantz will spearhead the development of Tune\u2019s transformative genetic tuning platform, which has the potential to target a broad range of common, complex, and multigenic diseases.<\/p>\n<p>\n\u201cDr. Jantz\u2019s experience in taking novel modalities from inception to preclinical and clinical-stage therapies makes him an ideal addition to our team. His knowledge in this area is unsurpassed, and we\u2019re eager to incorporate his scientific expertise as we advance our TEMPO genetic tuning platform,\u201d said Matt Kane, CEO of Tune Therapeutics.<\/p>\n<p>\nDr. Jantz co-founded Precision BioSciences in 2006 as co-inventor of a novel method for modifying the DNA-recognition properties of the I-Crel homing endonuclease, which in turn provided the foundation for the ARCUS genome editing platform. At Precision, he led the development of allogeneic CAR T and <i>in vivo<\/i> editing platforms, overseeing all research teams and serving on the board of directors. Dr. Jantz holds more than 50 patents relating to gene editing, gene therapy, and cancer immunotherapy, and is the author of more than a dozen gene-editing publications.<\/p>\n<p>\n\u201cI\u2019m thrilled to be joining the team at Tune,\u201d said Dr. Jantz. \u201cI\u2019m excited by the unique potential of the TEMPO platform to impact major world health challenges that I believe to be beyond the reach other technologies.\u201d<\/p>\n<p>\nAs Tune\u2019s new General Counsel, Zach Hale will oversee all of Tune\u2019s legal affairs. He previously served as Senior Vice President and Deputy General Counsel at Juno Therapeutics, and before that was a corporate attorney at the international law firm Latham &amp; Watkins LLP. He received his J.D. from Yale Law School and his B.A. <i>summa cum laude<\/i> from Harvard.<\/p>\n<p>\n\u201cZach\u2019s expertise specific to the biotechnology field makes him well-prepared to represent Tune as we rapidly expand,\u201d said Akira Matsuno, Co-Founder, President, and Chief Financial Officer at Tune. \u201cThe entire leadership team anticipates Zach and Derek will accelerate our success.\u201d<\/p>\n<p>\n\u201cI am honored to join the stellar group of scientists, engineers, and biopharmaceutical development professionals that have been assembled at Tune,\u201d said Hale. \u201cI look forward to supporting Tune in driving the development of cutting-edge epigenetic therapeutics, and making a serious difference in patients\u2019 lives.\u201d<\/p>\n<p>\n\u201cDerek and Zach are joining at a critical stage in our development,\u201d Kane added. \u201cTheir leadership will be decisive in advancing a new and transformative class of precision genetic-tuning treatments.\u201d<\/p>\n<p>\n<b>About Tune Therapeutics<\/b><\/p>\n<p>\nWith its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine.<\/p>\n<p>\nWith deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nE:<b> <\/b><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#111;:&#x6d;e&#x64;&#105;&#x61;&#64;t&#x75;&#110;&#x65;&#116;x&#x2e;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">med&#105;&#97;&#64;&#116;&#x75;&#x6e;&#x65;&#x74;&#x78;&#x2e;&#x63;om<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The genetic tuning innovator adds pioneering genetic medicine expert and an accomplished biotechnology lawyer to its management team. DURHAM, N.C. &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jantz, Ph.D., and General Counsel, Zachary Hale, J.D. Dr. Jantz comes to Tune with deep &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55642","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The genetic tuning innovator adds pioneering genetic medicine expert and an accomplished biotechnology lawyer to its management team. DURHAM, N.C. &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jantz, Ph.D., and General Counsel, Zachary Hale, J.D. Dr. Jantz comes to Tune with deep ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-10T13:05:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758977\/21\/derek.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel\",\"datePublished\":\"2023-04-10T13:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/\"},\"wordCount\":609,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005075\\\/en\\\/1758977\\\/21\\\/derek.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/\",\"name\":\"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005075\\\/en\\\/1758977\\\/21\\\/derek.jpg\",\"datePublished\":\"2023-04-10T13:05:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005075\\\/en\\\/1758977\\\/21\\\/derek.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005075\\\/en\\\/1758977\\\/21\\\/derek.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/","og_locale":"en_US","og_type":"article","og_title":"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel - Pharma Trend","og_description":"The genetic tuning innovator adds pioneering genetic medicine expert and an accomplished biotechnology lawyer to its management team. DURHAM, N.C. &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Today, leading epigenomic editing company Tune Therapeutics introduced two members to its leadership team: Chief Scientific Officer, Derek Jantz, Ph.D., and General Counsel, Zachary Hale, J.D. Dr. Jantz comes to Tune with deep ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-10T13:05:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758977\/21\/derek.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel","datePublished":"2023-04-10T13:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/"},"wordCount":609,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758977\/21\/derek.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/","url":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/","name":"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758977\/21\/derek.jpg","datePublished":"2023-04-10T13:05:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758977\/21\/derek.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230410005075\/en\/1758977\/21\/derek.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tune-therapeutics-strengthens-leadership-team-with-addition-of-dr-derek-jantz-as-chief-scientific-officer-and-zachary-hale-as-general-counsel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55642"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55642\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}